非小细胞肺癌相关性贫血研究进展  

Research progress in non-small cell lung cancer-related anemia

作　　者：熊柳冰[1] 陈蕾[1] 李秋丽[2] 张灏[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院肿瘤内科,广东汕头515031 [2]内蒙古民族大学医学院临床系,内蒙古通辽028043

出　　处：《转化医学杂志》2014年第2期74-78,共5页Translational Medicine Journal

摘　　要：贫血是非小细胞肺癌患者中较常见的表现,原因复杂且多样,常导致患者疲劳感,严重影响患者的生活质量、后续治疗及治疗效果,研究表明贫血可导致肿瘤耐药及侵袭性增强,降低非小细胞肺癌的放化疗疗效。非小细胞肺癌患者合并癌症贫血既与癌症本身病情进展有关,也与放疗或化疗的毒副作用相关,而贫血患者的血红蛋白水平变化是影响疗效及预后的可观测指标。对于非小细胞肺癌患者贫血治疗的干预,也与非小细胞肺癌患者预后紧密相关。促红细胞生成素(erythropoietin,EPO)的使用存在争议,但与化疗同时使用可以改善非小细胞肺癌患者的生活质量,值得开展前瞻性临床研究。Anemia is very common in patients with non-small cell lung cancer (NSCLC ), but the exact cause of anemia in this subset of patients remains unclear,possibly due to complex clinical settings.Patients with anemia usually presented with fatigue,which significantly compromise treatment outcome and undermine their quality of life (QOL).Studies have shown that anemia is tightly linked to drug resistance through increasing invasiveness of cancer cell,thereby reducing the efficacy of radiotherapy and chemotherapy for patients with NSCLC.It is reported that anemia in NSCLC patients is associated with cancer progression,as well as the side effects of radiotherapy and chemotherapy,and the dynamic change of hemoglobin level in patients with anemia might be recko-ned as an indicator of treatment outcome and prognosis.Effective intervention and treatment of ane-mia is closely related to the prognosis of patients with NSCLC.The clinical use of Erythropoietin (EPO)in cancer patients is still controversial,however,when utilized in conjunction with chemo-therapy,it can improve the quality of life in patients with NSCLC,which indicating that further pro-spective clinical study to validate its role in these patients is needed.

关 键 词：血红蛋白 非小细胞肺癌 生活质量 疗效 预后 

分 类 号：R556.9[医药卫生—血液循环系统疾病] R734.2[医药卫生—内科学]